Guidelines on the Management of Patients with PAD
This program will provide updates on the management of patients with peripheral artery disease and its impact on daily clinical practice. Pharmacotherapy and lifestyle modification is discussed here to help with a well-rounded treatment and management for peripheral artery disease. Revascularization therapy and its appropriateness in management of peripheral arterial disease is also discussed.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Marc Bonaca, MD, MPH
Professor of Medicine
Director of Vascular Research
University of Colorado School Medicine
Aurora, CO
Dr. Bonaca has reported the following relevant financial relationships or relationship with ineligible companies of any amount during the past 24 months:
Research grant/Consulting fees: Abbott Laboratories, Agios Pharmaceuticals, Inc., Alexion Pharma, Alnylam Pharmaceuticals, Inc., Amgen Inc., Angionetics, Inc., Anthos Therapeutics, ARCA Biopharma, Inc., Array BioPharma, Inc., AstraZeneca and Affiliates, Atentiv LLC, Audentes Therapeutics, Inc., Bayer and Affiliates, Beth Israel Deaconess Medical Center, Better Therapeutics, Inc., Boston Clinical Research Institute, Bristol-Meyers Squibb Company, Cambrian Biopharma, Inc., Cardiol Therapeutics Inc., CellResearch Corp., Cleerly Inc., Cook Regentec LLC, CSL Behring LLC, Eidos Therapeutics, Inc., EP Trading Co. Ltd., EPG Communication Holdings Ltd., Epizon Pharma, Inc., Esperion Therapeutics, Inc., Everly Well, Inc., Exicon Consulting Pvt. Ltd., Faraday Pharmaceuticals, Inc., Foresee Pharmaceuticals Co. Ltd., Fortress Biotech, Inc., HDL Therapeutics Inc., HeartFlow Inc., Hummingbird Bioscience, Insmed Inc., Ionis Pharmaceuticals, IQVIA Inc., Janssen and Affiliates, Kowa Research Institute, Inc., Kyushu University, Lexicon Pharmaceuticals, Inc., Medimmune Ltd., Medpace, Merck & Affiliates, Nectero Medical Inc., Novartis Pharmaceuticals Corp., Novo Nordisk, Inc., Osiris Therapeutics Inc., Pfizer Inc., PhaseBio Pharmaceuticals, Inc., PPD Development, LP, Prairie Education and Research Cooperative, Prothena Biosciences Limited, Regeneron Pharmaceuticals, Inc., Regio Biosciences, Inc., Saint Luke’s Hospital of Kansas City, Sanifit Therapeutics S.A., Sanofi-Aventis Groupe, Silence Therapeutics PLC, Silence, Smith & Nephew plc, Stanford Center for Clinical Research, Stealth BioTherapeutics Inc., State of Colorado CCPD Grant, The Brigham & Women's Hospital, Inc., The Feinstein Institutes for Medical Research, Thrombosis Research Institute, University of Colorado, University of Pittsburgh, VarmX, Virta Health Corporation, Worldwide Clinical Trials Inc., WraSer, LLC, and Yale Cardiovascular Research Group, and AHA SFRN under award numbers 18SFRN3390085 (BWH-DH SFRN Center) and 18SFRN33960262 (BWH-DH Clinical Project).
Alik Farber, MD, MBA, FACS, DFSVS
Interim Chair, Department of Surgery
Professor of Surgery and Radiology
Boston University Chobanian & Avedisian School of Medicine
Interim Chief, Department of Surgery
Associate Chief Medical Officer for Surgical Services
Chief, Division of Vascular & Endovascular Surgery
Boston Medical Center
Boston, MA
Dr. Farber has reported the following relevant financial relationships or relationship with ineligible companies of any amount during the past 24 months:
Consulting fees: BiogenCell, LeMaitre, and Sanifit.
Naomi Hamburg, MD, MS
Joseph Vita Professor of Cardiovascular Medicine
Boston University Chobanian and Avedisian School of Medicine
Boston, MA
Dr. Hamburg Dr. Farber has reported the following relevant financial relationships or relationship with ineligible companies of any amount during the past 24 months:
Consulting fees: Boston Scientific, and Fukuda.
Connie N. Hess, MD, MHS
Associate Professor of Medicine
Division of Cardiology
University of Colorado School of Medicine
Aurora, CO
Dr. Hess has reported the following relevant financial relationships or relationship with ineligible companies of any amount during the past 24 months:
Research fees: Amgen, Bayer, and Janssen
Schuyler Jones, MD
Associate Professor of Medicine
Duke University Health System
Durham, NC
Dr. Joneshas reported the following relevant financial relationships or relationship with ineligible companies of any amount during the past 24 months:
Research fees: Bayer, Bristol Myers Squibb, Merck, and Novartis.
Manesh R. Patel, MD
Richard S. Stack Distinguished Professor
Chief, Division of Cardiology
Co-Director Duke Heart Center
Duke Clinical Research Institute
Duke University
Durham, NC
Dr. Patel has reported the following relevant financial relationships or relationship with ineligible companies of any amount during the past 24 months:
Research Fees: AstraZeneca, Bayer, Janssen, Mytonomy, and Procyrion
Consulting fees: Bayer, Janssen, and Novartis
Reviewers/Content Planners/Authors:
After participating in this educational activity, participants should be better able to:
This activity has been designed to meet the educational needs of Cardiologists and Hepatologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with peripheral arterial disorder.
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC), Total CME, LLC and Duke Heart OTG. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until September 20, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hours/0.10 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-9999-24-095-HO1-P. This learning activity is Knowledge based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Release Date:
Expiration Date:
